Characterization of circRNA‑associated ceRNA networks in patients with nonvalvular persistent atrial fibrillation

  • Authors:
    • Yangyang Zhang
    • Xianting Ke
    • Jingjing Liu
    • Xiue Ma
    • Yi Liu
    • Dandan Liang
    • Luxin Wang
    • Changfa Guo
    • Yiwei Luo
  • View Affiliations

  • Published online on: November 26, 2018     https://doi.org/10.3892/mmr.2018.9695
  • Pages: 638-650
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Circular RNAs (circRNAs) are non-coding RNAs forming closed-loop structures, and their aberrant expression may lead to disease. However, the potential network of circRNA‑associated competing endogenous RNA (ceRNA) involved in nonvalvular persistent atrial fibrillation (NPAF) has not been previously reported. In the present study, four left atrial appendages (LAA) of patients with NPAF and four normal LAAs were examined via RNA sequencing, and their potential functions were investigated via bioinformatics analysis. The circRNA‑enriched genes were analyzed using Gene Ontology (GO) categories, while the enrichment of circRNAs was detected via the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. A total of 296 significantly dysregulated circRNA transcripts were obtained, with 238 upregulated and 58 downregulated. A number of circRNAs were further confirmed using reverse transcription‑quantitative polymerase chain reaction analysis. Furthermore, the more comprehensive circRNA‑associated ceRNA networks were examined in patients with NPAF. GO categories and KEGG annotation analysis of circRNAs revealed that the circRNA‑associated ceRNA networks were likely to influence AF though alterations in calcium and cardiac muscle contraction. The circRNA‑associated ceRNA networks revealed that dysregulated circRNAs in NPAF may be involved in regulating hsa‑microRNA (miR)‑208b and hsa‑miR‑21. To the best of our knowledge, this study presents the circRNA‑associated ceRNA networks in NPAF for the first time, which may have potential implications for the pathogenesis of AF. This study reveals a potential perspective from which to investigate circRNAs in circRNA‑associated ceRNA networks (hsa_circRNA002085, hsa_circRNA001321) in NPAF, and provides a potential biomarker for AF.

Introduction

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia in humans, characterized by irregular and rapid electrical activity of the atria (1,2). In 2010, AF affected ~33.5 million people, causing ~5 million new cases each year worldwide (3,4). AF causes 130,000 mortalities/year in the USA (5) and affects 2–3% of the European population (4,6,7). The number of patients with AF is predicted to increase rapidly in the coming decades and to gradually reduce quality of life (8,9). In Asia, the number of patients with AF and AF-associated stroke is estimated to reach 72 million and 2.9 million by 2050, respectively (3,10). Warfarin is commonly applied to treat nonvalvular persistent atrial fibrillation (NPAF) and research on NPAF has been extensive (11,12), although the current treatment options remain inadequate. Thus, it is necessary to identify a novel biomarker for the prediction, diagnosis and treatment of NPAF.

Circular RNAs (circRNAs), non-coding RNAs identified in 1991 (13), regulate gene expression and act as microRNA (miRNA) ‘sponges’ by competing with endogenous RNA (ceRNA) networks to suppress specific miRNA activity (14,15). circRNAs are associated with numerous diseases and may serve an important role in diagnosis or pathogenesis (16,17). Previous studies have demonstrated that circRNA-miRNA-mRNA networks are likely to be involved in certain diseases (18,19). However, there is little research regarding the functions of circRNAs in AF, particularly NPAF. The present study aimed to identify a novel biomarker for diagnosis of AF.

Materials and methods

Ethics approval statement

Written informed consent was obtained from patients prior to collection of left atrial appendages (LAAs), which were abandoned due to surgical techniques. The present study was conducted in accordance with the Declaration of Helsinki, and all experimental procedures were approved by the Ethics Committee of Shanghai East Hospital (approval no. 040–2017) as per relevant guidelines and regulations (clinical research registration no. ChiCTR-RRC-17014230).

Clinical specimens

A total of four male patients with NPAF without valvular disease as an AF group, and four healthy male organ donors as a control group, were recruited between January 2016 and December 2017. AF specimens were collected from the LAAs of patients with NPAF during LAA excision along with surgical atrial fibrillation ablation. Normal LAAs were collected from healthy donors. Excised LAAs were stored in RNA later in −20°C prior to RNA extraction. Characteristics of the four patients are listed in Table I.

Table I.

Demographic characteristics of patients.

Table I.

Demographic characteristics of patients.

No.Age, yearsSexNYHAINRCoronary arteryDisease complicationsDuration of AF, yearsDrug treatments
164MaleII–III3.38NegativeType II diabetes2Warfarin, furosemide, spironolactone and Cordarone
276MaleII–III0.92NegativeNegative3Warfarin, Cordarone, spironolactone, furosemide and Betaloc
369MaleII–III2.03NegativeNegative4Warfarin, Betaloc, furosemide, spironolactone and Cordarone
460MaleII–III2.00NegativeNegative2Warfarin, furosemide and spironolactone

[i] NYHA, New York Heart Association; INR, International Normalized Ratio; AF, atrial fibrillation.

RNA extraction and qualification

Total RNA was isolated using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer's protocol, and dissolved in RNase-free water. RNA purity was assessed using a Nanodrop ND-2000 device (Thermo Fisher Scientific, Inc., Wilmington, DE, USA) with an absorbance (A)260/A280 of 1.8–2.0, and integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA). The RNA integrity values of the RNAs obtained from the eight LAA specimens were 7.9, 7.7, 7.1, 7.3, 6.8, 7.2, 8.1 and 7.5, respectively.

RNA sequencing

Sequencing libraries were prepared as recommended by the VAHTS™ Total RNA-seq (H/M/R) Library Prep kit (Illumina, Inc., San Diego, CA, USA). Ribosomal RNA was removed using target-specific probes, RNase H and DNA polymerase I (Finnzyme; Thermo Fisher Scientific, Inc., Waltham, MA, USA), and subsequently fragmented into pieces. Using reverse transcriptase and random primers, the RNA fragments were copied to the first strand of cDNA: 1 cycle of 25°C for 10 min; and 1 cycle of 50°C for 15 min and 85°C for 5 min, and the second strand was synthesized using DNA polymerase I, RNase H and dNTPs (dUTP, dATP, dGTP and dCTP; Invitrogen; Thermo Fisher Scientific, Inc.). Subsequently, single ‘A’ bases were added to the fragments of cDNA and then the adapter was ligated. To select the appropriate fragment size for sequencing, the library fragments were selected with VAHTSTM DNA Clean Beads (Vazyme Biotech Co., Nanjing, China). The second strand of cDNA was digested using an UDG (uracil-N-glycosylase) enzyme (Thermo Fisher Scientific, Inc.). Following cluster generation, 150-bp paired-end reads were produced by sequencing the libraries on the Illumina, Inc. Hiseq X10 platform.

Differential expression analysis

The expression levels of circRNAs were measured by RNA sequencing and expressed as ‘transcripts per kilobase million’. Differentially-expressed circRNAs were analyzed using DESeq2 based on the negative binomial distribution test, and the thresholds were P<0.05 and fold-change (FC) >2. P-values were calculated using a statistical algorithm (20).

Validation of circRNAs by reverse transcription-quantitative PCR (RT-qPCR)

A number of differential circRNAs were randomly selected to test the accuracy of the RNA sequencing data by RT-qPCR. Total RNA was reverse transcribed into cDNA using PrimeScript™ RT Reagent kit (Takara Bio, Inc., Shiga, Japan) according to standard procedures. A total reaction volume of 20 µl, including 1,000 ng RNA, 4 µl 5X PrimeScript RT Master Mix and RNase Free dH2O. The thermocycling conditions were as follows: 37°C for 15 min, then 10 sec at 85°C. RT-qPCR was performed with a SYBR Green kit (Promega Corporation, Madison, WI, USA) in the QuantStudio™ 6 Flex system (Applied Biosystems; Thermo Fisher Scientific, Inc.), The reactions were incubated in 384-well plates at 50°C for 2 min, and 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min, followed by a dissociation curve. The internal reference was 18s rRNA (Applied Biosystems; Thermo Fisher Scientific, Inc.). Relative expression was quantified using the 2−ΔΔCq method (21). The primers are listed in Table II.

Table II.

The list of circRNAs qRT-PCR primers between NPAF and controls.

Table II.

The list of circRNAs qRT-PCR primers between NPAF and controls.

CircRNAForward primerReverse primer
hsa_circRNA011430 CGAGCAGTACCCCACAATGG TCTGTTGGCATGCTGCTGAA
hsa_circRNA015317 ATTAGGCAGACTCTTCAAAACGC AAACCCCCACCCACAAAGCA
hsa_circRNA016587 TAGGCACAGCTCCTCCAGAT TGTGAGATGCTTCACTGCATTC
hsa_circRNA003585 GCTGCCCAATGATCTGCTTG CCCTGCTTGCAGCTGTAGAAT
hsa_circRNA015019 GGAGCCAAAGCCTAATCCGC CTGCTGCCAAGGCATACTCA
hsa_circRNA003126 ATGGACTGGCGGATCAAGGA TGGCCACCAGTCACAAGGTA
Gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis

The differential or target genes of circRNAs were estimated and determined using GO enrichment analysis at the perl module (GO: TermFinder, http://search.cpan.org/dist/GO-TermFinder/) The KEGG enrichment of target genes of differential circRNAs was tested using R functions (22) (P hyper and Q value). The significantly-enriched GO terms and KEGG pathways met the criterion of corrected P<0.05.

circRNA-ceRNA interaction prediction

The circRNA-miRNA interactions were predicted using TargetScan 6.0 (http://www.targetscan.org/vert_60/), which identifies miRNA targets and determines whether or not a given target is conserved across a given set of species. The sequences of circRNAs were predicted as miRNA binding seed sequence sites using potential miRNA response elements.

Statistical analysis

Statistical analyses was conducted using SPSS 19.0 software (IBM Corp., Armonk, NY, USA). When comparing two groups of profile differences, the fold-change (i.e. the ratio of the group averages) between the groups for each circRNA was computed. The differential expression of circRNAs was assessed using a Student's unpaired t-test. Error bars in the figures represent the means ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.

Results

Overview of RNA-seq

No significant between-group difference was identified in the expression levels of 15,777 circRNAs. In total, 296 differential circRNAs were identified with FC>2 and P<0.05. Among them, 238 were upregulated and 58 were downregulated in NPAF tissues compared with the controls (Figs. 1 and 2). The upregulated circRNAs (data not shown; available at http://1drv.ms/w/s!Al7sl_MjqbmWgQDki8ZjwTQd2j0H) with ‘FC >2’ and downregulated circRNAs (data not shown; available at http://1drv.ms/w/s!Al7sl_MjqbmWgQEKE-v8hCjzTevu) are listed. A number of the circRNAs were used in the subsequent analysis.

Validation of circRNAs by RT-qPCR

A total of six dysregulated circRNAs were randomly selected as representatives to validate the RNA sequencing data by RT-qPCR, and the primers are listed in Table II. All circRNAs were well-validated by qPCR, and the directions of the changes were consistent with the RNA-seq data (Fig. 3). The RT-qPCR data suggested the RNA-seq-identified circRNAs are reliable and require further research.

Functional enrichment analysis: GO and KEGG pathway analysis

The differential circRNAs were annotated with GO, and were identified to be involved in the following functions: Cell component, biological process and molecular function (Fig. 4). GO analysis revealed that a number of functional pathways were enriched. Some of the top 10 terms were as follows: ‘Voltage-gated calcium channel activity is involved in AV node cell action potential’ in cell component GO (no. 0086056); ‘cardiac muscle contraction is regulated by calcium ion signaling’ in bioprocess GO (no. 0010882); ‘release of sequestered calcium ion into cytosol is regulated by sarcoplasmic reticulum’ in bioprocess GO (no. 0010880); and ‘regulation of cardiac muscle cell action potential is involved in regulation of contraction’ in bioprocess GO (no. 0098909), which were the most closely associated with AF. These criteria from the GO analysis were also applied to the KEGG enrichment analysis. The top 20 KEGG pathway analysis demonstrated that the most significant pathways involved in AF were ‘arrhythmogenic right ventricular cardiomyopathy’ (no. ko05412) and ‘cardiac muscle contraction’ (no. ko04260; Fig. 5).

Construction of circRNA-ceRNA interaction network

To analyze the interaction between differential circRNAs and ceRNAs, a ceRNA network in NPAF was investigated using RNA sequencing data. To examine which circRNAs were vital for NPAF progression, nine differential circRNAs were selected from those with calcium-associated parental genes. Complete sequences of hsa_circRNA-011785, −001321, −003878, −002085, −003884, −003876, −007410, −007411 and −004558 are listed in Table III. Details are provided in Table IV. A representative network of circRNAs and miRNAs is presented in Fig. 6. The interactions between hsa_circRNA002085 and hsa-miRNA (miR)-21, and between hsa_circRNA001321 and hsa-miR-1, suggest the possibility of an NPAF regulatory mechanism.

Table III.

Complete sequence of differentially expressed circRNAs between the NPAF and control groups.

Table III.

Complete sequence of differentially expressed circRNAs between the NPAF and control groups.

circ_IDSequence
hsa_circRNA011785 AAAATGTAGGCCGGTTAATCACTCCTGCCAAAAAGCTTGAAGATACAATACGTCTTGCTGAACTAGTCATTGAAGTTCTTCAGCAAAATGAGGAGCACCACGCAGAGCCACATGTTGATAAAGGAGAAGCCTTTGCGTGGTGGTCAGATTTAATGGTGGAGCATGCGGAGACGTTCCTGTCACTCTTTGCAGTAGACATGGATGCAGCCTTAGAGGTGCAACCTCCAGACACATGGGACAGTTTTCCACTATTTCAGCTGCTGAATGATTTTCTCCGTACTGACTATAATTTGTGCAATGGAAAATTTCACAAACACCTGCAAGACCTGTTTGCCCCACTTGTTGTTAGATATGTGGATCTGATGGAGTCCTCAATTGCACAATCCATTCACAGGGGCTTTGAGCGGGAGTCATGGGAACCAGTCAAGAGTTTAACCAGTAACCTACCCAATGTGAACCTACCCAATGTGAACCTTCCCAAAGTACCAAATCTACCAGTTAACATCCCTCTAGGCATCCCACAAATGCCTACTTTTTCGGCACCGTCATGGATGGCTGCTATATATGATGCGGATAATGGGTCAGGCACCTCAGAAGATCTGTTTTGGAAACTTGACGCCCTTCAGACCTTCATTCGGGACCTGCACTGGCCTGAAGAAGAGTTTGGAAAGCACCTGGAACAACGGCTGAAGTTGATGGCAAGTGACATGATCGAATCTTGTGTCAAAAGAACCAGGATTGCATTTGAAGTTAAGCTGCAAAAAACCAGTCGATCAACAGATTTTCGAGTCCCACAGTCAATATGCACCATGTTTAATGTTATGGTTGATGCCAAAGCTCAATCAACAAAACTTTGCAGCATGGAAATGGGCCAAGAGCATCAATACCATTCAAAAATAGACGAACTAATTGAAGAAACTGTTAAAGAAATGATAACACTCTTGGTTGCAAAGTTCGTTACTATCTTGGAAGGAGTGCTGGCAAAATTATCCAGATATGACGAAGGGACTTTGTTTTCTTCTTTTCTGTCATTTACCGTGAAGGCAGCTTCCAAATATGTGGATGTACCTAAACCCGGGATGGACGTGGCCGACGCCTACGTGACTTTCGTCCGCCATTCTCAGGATGTCCTGCGTGATAAGGTCAATGAGGAGATGTACATAGAAAGGTTATTTGAT
hsa_circRNA001321 GAGGAATTAGAAGGTCTTCATCTATGTCTTATGTTGATGGCTTCATAGGGACATGGCCCAAAGAGAAAAGATCATCAGTGCATGGCGTATCATTTGATATTTCTTTTGATAAAGAAGATAGTGTACAGAGATCCACTCCAAACCGAGGAATCACTCGTTCTATTAGTAATGAAGGACTTACTCTGAACAACAGTCATGTATCTAAACACATTAGGAAAAATTTGTCCTTCAAGCCAATAAATGGAGAAGAGGAAGCAGAGAGCATTGAAGAAGAACTTAATATAGATTCTCACAGTGACCTCAAATCTTGTGTGCCCCTTAACACAAATGAACTAAATTCTAATGAGAATATTCATTACAAGCTTCCAAATGGAGCTTTACAAAATAGAATACTTCTTGACGAGTTTGGCAATCAGATCGAGACACCAAGCATTGAAGAAGCATTACAAATAATTCATGATACTGAAAAATCTCCTCATACACCTCAGCCAGACCAAATTGCTAATGGCTTCTTTCTTCATAGTCAAGAAATGAGTATCTTAAATTCAAATATCAAGTTAAATCAATCTAGTCCTGATAATGTAACTGATACGAAAGGTGCCTTGAGTCCCATAACTGACAATACTGAAGTAGACACTGGAATTCACGTTCCTTCAGAAGATATTCCTGAAACTATGGACGAAGATTCTTCGTTGAGAGATTATACTGTAAGCTTGGACTCTGACATGGATGATGCATCTAAATTTCTTCAGGATTATGATATTCGAACTGGCAACACCAGGGAAGCTTTGAGTCCTTGTCCAAGTACTGTAAGTACCAAGTCTCAGCCAGGCAGCAGTGCTTCTTCTAGTTCTGGAGTTAAAATGACCAGCTTTGCTGAACAAAAATTCAGGAAACTGAATCATACCGATGGAAAAAGTAGTGGAAGCAGTTCTCAAAAAACTACACCAGAAGGCTCTGAACTTAATATTCCTCATGTGGTTGCTTGGGCACAAATTCCAGAAGAAACAGGGCTTCCACAGGGACGGGACACTACCCAGCTGTTGGCCTCTGAAATGGTGCATCTTAGGATGAAACTAGAAGAAAAGAGGCGTGCTATAGAAGCCCAGAAAAAGAAAATGGAAGCTGCTTTTACCAAACAGAGACAGAAAATGGGAAGGACAGCATTCCTTACTGTAGTGAAAAAGAAAGGGGATGGGATATCTCCTCTACGAGAGGAAGCGGCGGGTGCAGAAGATGAGAAAGTATATACTGATCGAGCAAAAGAAAAGGAATCACAAAAAACTGATGGACAAAGGAGCAAGTCACTGGCAGATATAAAAGAGAGCATGGAGAATCCTCAAGCCAAATGGCTAAAGTCTCCAACTACACCTATTGATCCTGAGAAGCAGTGGAACCTGGCAAGCCCCTCAGAAGAAACTTTAAATGAAGGAGAGATTTTAGAATATACCAAATCCATTGAAAAGTTAAATTCATCCCTGCATTTTCTACAACAAGAAATGCAACGCTTGTCACTTCAGCAGGAGATGTTAATGCAGATGAGAGAGCAACAATCTTGGGTGATTTCACCTCCACAACCCTCTCCACAGAAACAGATTCGAGATTTTAAGCCTTCTAAGCAGGCAGGCCTGTCATCAGCCATTGCACCATTCTCCTCAGACTCCCCTCGTCCTACTCACCCATCTCCACAGTCTTCTAACAGGAAAAGTGCATCTTTTTCTGTTAAAAGTCAAAGGACTCCTAGGCCAAATGAGTTAAAAATAACACCTTTGAATCGAACCTTGACACCTCCTCGGTCTGTGGATAGCCTTCCTCGGTTAAGGAGGTTTTCACCAAGTCAAGTTCCTATTCAAACTAGGTCATTTGTATGTTTTGGGGATGATGGAGAACCTCAGTTAAAGGAATCCAAACCTAAAGAGGAAGTTAAAAAGGAGGAATTGGAATCCAAAGGGACTTTGGAACAGCGTGGACATAATCCAGAAGAAAAGGAAATCAAACCTTTTGAGTCAACAGTCTCTGAAGTCCTATCACTGCCTGTCACAGAGACTGTATGTCTGACACCAAATGAGGACCAATTGAATCAACCCACAGAACCCCCTCCTAAACCCGTTTTCCCACCCACTGCTCCAAAAAATGTTAATCTGATTGAAGTTTCCCTCTCAGATTTGAAACCCCCTGAAAAGGCTGATGTACCTGTTGAAAAATATGATGGAGAAAGTGATAAAGAACAATTTGATGATGACCAGAAAGTATGCTGTGGATTCTTTTTTAAGGATGATCAAAAAGCAGAAAATGATATGGCAATGAAACGGGCAGCTTTGTTGGAGAAAAGATTAAGAAGGGAAAAGGAAACTCAGCTCCGGAAACAACAGTTGGAAGCAGAAATGGAGCATAAGAAGGAGGAAACAAGGCGTAAAACTGAGGAAGAACGTCAGAAGAAAGAAGATGAGAGAGCACGCAGAGAATTTATTAGGCAAGAATATATGAGGCGGAAACAACTGAAATTCTAATGGAAGATATGGATACAGTAATTAAACCCCGTCCTCAAGTAGTAAAACAAAAAAAACAGCGACCAAAATCTATTCACAGAGATCATAGAATCCCCCAAAACACCAATAAAGGGTCCTCCAG
hsa_circRNA003878 GTCAGGATCGTGTGATTGTAAACTAGTCAGGTCAGGGTCGTGTGATTGTAAACTAGTCAGGTCAGGGTCGTGTGATTGTAAACTAGTCAG
hsa_circRNA002085 TGCTGGGATTACAGGCGTGACCATGGCACCGAGAACAATTTTTTGAAATTTAAGTTTTGGTGTTAAAGGTTTGGGTCAAGTTAAGCAGAGCTTGGGCTTGACACATATGTACACACGTGTGTGTGGGTGCGATGTATGTATTCTGCAACTGGCTATGACACCAATGCCCAGATGTCAAGTGGGAAATTTTCCAAGTTCTTGACAGCATCCAAGCATATATACTTTAGGCAGATACTTATATTCTTTGGTCTGGCAATGAGTGAGGAGAATAATAGATGAGACCTTTGGAAACGATGAAAATGATCATTACAGACCCATCCACACTTGATAGTTGGAGCAGTTGTGCCTGGAGGTGGATTGGGAGAACTTCTCTTTCGAGCTTTCTGAAGTTTTCCTTTAAATCAGTTGAGCTATTGATATAAAAATTGTCTCAGAGTCCTAATATGCTTATTATACATTTTGTAGTTGGTTATAGCTCCAAGTGACTCAGTCACCAGAAAAGTCACTTGAAAGTTGGTGTATCTCTACAAAACCTTGGTGAACATTTAAATCACCTTTTTAAATATTACACTCTTCATGGAACTTTACTTTTAGTAATGTCAAACATCTGCCTACAAAATGGAATGTTATTTTACATGTATACTAACTTGTTCTTCAAAATGCAGCACCTCCTTTCACTATACAGACGGTCCTTGACATACACTGGTTCAACTTAAGATTGTGCAAGTTTATTACAAATTTTTCAGGACATAACCTTATCATAAGTCAAGGTCTGAACTTTACGATGGTTTGACGTCAGACTTTTTACTGGGTCTGTCCACGTGTTAAGTACATTTTGAGTTACCATATTTTCTATTTATGATGGGTTTAGTGAAGTGTAACTCTATCATAAGTTGGGGAGCATCTGTGTTGCCAAAACCACTGGAGGGCTACAATATGGCTGGAGGGAATGGAAGAATTTTTCTGGTATATAGAAAGAAGTGAGGCTGACATTTGCAGGCAGAACTGCTGCTTTATCGCAAGGTGACATAGTCTTTTTCCACTTTAAGAGCCTAGTAGCAGTCCCTAGAAATCACTGAAATCATCTTTGAGATATATAAGAGTGTAAGGTTTATATAGGAATCCCTGCAACTTCACACATTTGAGAAGGAACAGGATAGGCCTCCCTTCCTCTGTGGATTCAGGGGCTCCGTAATTATCAAGGGAAGGTATAAGTTTCACATAATACCTACAGGGCCTTTCATTTTCATTTCATGCATACTATTTTACTTAATTTTGAGCATCTTAGAATTGCTTGCTTCAAGTTATAAGTAGATAGTTTTTGAAATTAATTTGCTTCCTAAAGCAATTCATTTATTGTGCTCAGATTTTGCTCACTTGAAAGTCCTATATTCTGTGTAGAACTTGGAATTCTATATAAACAGAACAATGGTTTGAATTGCAAAAAAAGCCCATGATCAGTATCTTAGTTTGCCAATGGCTGGGCATGGTGGCTCATGCCTGTCATCCCAACA
hsa_circRNA003884 GTGTGATTGTAAACTAGTAAGGTCAGGATCGTGTGATTGTAAAGTAGTCAGGTCAGGATCGTGTGATTGTAAACTAGTCAGGTCAGGGTC
hsa_circRNA003876GTCAGGGTCGTGTGA TTGTAAACTAGTCAG
hsa_circRNA007410 GCAGAGGAAAATATTGACTTATTAGATGATGGCTCTAATTCTTTTGCAACTGACTTGTCATCAGGAACTATTAACCACAAGAAATACATCAAGTTTTCTAAAACAATAGAGAAGGAAATTTCACCGGAAATTAGGAGTTTGAGCCCAGAATATAAAAAAATATTTGAAACATCAATAATCTTTTGTGGAGAAGAAAAGTCCTCTGATTTTTCAGGAGAAAAAAAAGTTGGGAGAAAGAGTTTACAAGTACAACAGCACAGTAAAAGAACTGAGATTATCCCTCCTTTTCTGAAGCTGTCAAAGGAGAAGGTGACAAGGAAAGAAAACTCTTTATGCAAGTTGCCGAATCAGTACAGCGTTCACAAGACTTCATCACCTCTTTGTACATCTTCTGCAATTACTCGGGAAAAGGAAATGCTGTCTAACCTCTACATGACATTATATGATGAAGTAACCCATGGATATTTACACTCAAAAGAATTAAGTGCACTTCATAAAGCCTGTAAAATTTTTAGTAAAATTCGAAGTGGTAAGATTTATGTGAATGATCTTCCAGTGATCCTTTGCATCTTGAGAATTTCTATAAGTGATTTAGAAATGCGACAGGCACTAAAGACTGTTGATATTGATGCATTCCAGGATGCCTTGAAGATTTTCTGTAGGATAAAAGGTGGTCGAGTTTCAACTGATGACGTGTTTGCTGTTTTGGATAGCATGGGTATCCCTATAAACCGTGAAATTTTAGAAGAAGTGACAAAACATACCTATATTGACA
hsa_circRNA007411 AGGAAAATATTGACTTATTAGATGATGGCTCTAATTCTTTTGCAACTGACTTGTCATCAGGAACTATTAACCACAAGAAATACATCAAGTTTTCTAAAACAATAGAGAAGGAAATTTCACCGGAAATTAGGAGTTTGAGCCCAGAATATAAAAAAATATTTGAAACATCAATAATCTTTTGTGGAGAAGAAAAGTCCTCTGATTTTTCAGGAGAAAAAAAAGTTGGGAGAAAGAGTTTACAAGTACAACAGCACAGTAAAAGAACTGAGATTATCCCTCCTTTTCTGAAGCTGTCAAAGGAGAAGGTGACAAGGAAAGAAAACTCTTTATGCAAGTTGCCGAATCAGTACAGCGTTCACAAGACTTCATCACCTCTTTGTACATCTTCTGCAATTACTCGGGAAAAGGAAATGCTGTCTAACCTCTACATGACATTATATGATGAAGTAACCCATGGATATTTACACTCAAAAGAATTAAGTGCACTTCATAAAGCCTGTAAAATTTTTAGTAAAATTCGAAGTGGTAAGATTTATGTGAATGATCTTCCAGTGATCCTTTGCATCTTGAGAATTTCTATAAGTGATTTAGAAATGCGACAGGCACTAAAGACTGTTGATATTGATGCATTCCAGGATGCCTTGAAGATTTTCTGTAGGATAAAAGGTGGTCGAGTTTCAACTGATGACGTGTTTGCTGTTTTGGATAGCATGGGTATCCCTATAAACCGTGAAATTTTAGAAGAAGTGACAAAACATACCTATATTGACAGTGA
hsa_circRNA004558 ACCAATCTGACCTTCGTTGGCTGCGTGGGCATGCTGGATCCTCCGAGAATCGAGGTGGCCTCCTCCGTGAAGCTGTGCCGGCAAGCAGGCATCCGGGTCATCATGATCACTGGGGACAACAAGGGCACTGCTGTGGCCATCTGTCGCCGCATCGGCATCTTCGGGCAGGATGAGGACGTGACGTCAAAAGCTTTCACAGGCCGGGAGTTTGATGAACTCAACCCCTCCGCCCAGCGAGACGCCTGCCTGAACGCCCGCTGTTTTGCTCGAGTTGAACCCTCCCACAAGTCTAAAATCGTAGAATTTCTTCAGTCTTTTGATGAGATTACAGCTATGACTGGCGATGGCGTGAACGATGCTCCTGCTCTGAAGAAAGCCGAGATTGGCATTGCTATGGGCTCTGGCACTGCGGTGGCTAAAACCGCCTCTGAGATGGTCCTGGCGGATGACAACTTCTCCACCATTGTGGCTGCCGTTGAGGAGGGGCGGGCAATCTACAACAACATGAAACAGTTCATCCGCTACCTCATCTCGTCCAACGTCGGGGAAGTTGTCTG

[i] circRNA, circular RNA.

Table IV.

Parental genes corresponding to the differentially expressed circRNAs.

Table IV.

Parental genes corresponding to the differentially expressed circRNAs.

A, upregulated circRNAs

circ_IDP-valueFCChrStartEndStrLociGene listDescription
hsa_circRNA0038780.003525   15.10051chr12   2255950   2256039ExonCACNA1CCalcium voltage-gated channel subunit α1C
hsa_circRNA0038840.02730694.9909chr12   2256001   2256090ExonCACNA1CCalcium voltage-gated channel subunit α1C
hsa_circRNA0038760.033396116.6174chr12   2255950   2255979ExonCACNA1CCalcium voltage-gated channel subunit α1C
hsa_circRNA0074110.042442295.9099chr17   47335200   47361525+ExonEFCAB13EF-hand calcium binding domain 13
hsa_circRNA0074100.041746522.6585chr17   47335196   47361521+ExonEFCAB13EF-hand calcium binding domain 13
hsa_circRNA0020850.025361101.3261chr10   18508039   18509552ExonCACNB2Calcium voltage-gated channel auxiliary subunit β2
hsa_circRNA0117850.0261382.935789chr3   62438104   62499268ExonCADPSCa2+ dependent secretion activator
hsa_circRNA0013210.0126865.92702chr1200847640200853495+ExonCAMSAP2Calmodulin regulated spectrin associated protein family member 2

B, downregulated circRNAs

circ_IDP-valueFCChrStartEndStrLoci GeneList Description

hsa_circRNA0045580.0079210.08415chr12110340659110342448+ExonATP2A2ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

[i] circRNA, circular RNA; FC, fold-change; Chr, chromosome; Str, strand.

Discussion

In total, 296 differential circRNAs were identified between NPAF tissues and the controls (FC>2; P<0.05), including 238 upregulated circRNAs and 58 downregulated circRNAs. To validate the RNA sequencing data, six representative dysregulated circRNAs (hsa_circRNA-011430, −015317, −016587, −003585, −015019 and −003126) were selected. The RT-qPCR results suggested that the RNA sequencing-identified circRNAs are reliable and merit further research. The significantly dysregulated circRNAs in patients with NPAF may serve a regulatory role in the mechanism of AF progression.

Unlike linear RNAs, circRNAs are covalently linked to form closed-loop structures without 5′ caps or 3′ tails (18,2325). In circRNAs, a downstream splice donor is joined by ‘back-splicing’ to the upstream splice acceptor (17,26,27). circRNAs are associated with, and serve important roles in the diagnosis and pathogenesis of, numerous diseases (16,17), including colorectal cancer (28), breast cancer (29) and gastric cancer (30). Furthermore, circRNAs are able to upregulate the expression levels of fibrosis-associated genes in cardiac fibroblasts (31). Other studies have reported that a circRNA-ceRNA network may be present in certain diseases (18,19). However, the circRNAs and circRNA-ceRNA network leading to AF remain to be elucidated.

AF remains a common cause of stroke, heart failure and cardiovascular mortality worldwide. AF may occur idiopathically, which is associated with familial inherent specific genetic mutations (32). Certain mechanisms leading to AF are primarily associated with the remodeling of ion channel functions, including those of K+ channels, and cellular Ca2+ handling and release (3336). Other mechanisms of AF include mutations and the abnormal expression of genes encoding cardiac ion channels, including potassium voltage-gated channel subfamily Q member 1, potassium voltage-gated channel subfamily E regulatory subunit 2, potassium voltage-gated channel subfamily J member 2 (KCNJ2) and sarcoplasmic/endoplasmic reticulum calcium ATPase 2A (SERCA2) (36).

For instance, calcium gene expression was identified to be abnormal in AF (37), and was hypothesized to contribute to the propensity for structural remodeling in AF. The calcium signaling pathway is essential in the electrical remodeling of AF and may induce the recurrence of AF (37). Abnormalities in intracellular Ca2+ handling are crucially involved in AF-initiated focal activity and perpetuation through rapidly firing foci and reentry (37).

GO analysis performed using differential circRNAs between the NPAF and control groups demonstrated that a number of functional pathways were enriched. The primary cell component was GO (no. 0086056) ‘voltage-gated calcium channel activity is involved in AV node cell action potential’. The main bioprocesses were GO (no. 0010882) ‘cardiac muscle contraction is regulated by calcium ion signaling’, GO (no. 0010880) ‘release of sequestered calcium ion into cytosol is regulated by sarcoplasmic reticulum’ and GO (no. 0098909) ‘regulation of cardiac muscle cell action potential is involved in regulation of contraction’. The specific genomes were ‘CACNB2, CACNA1C’ (GO:0086056); ‘SLC8A1, ATP2A2, CACNA1C, ANK2, RYR2’ (GO:0010882); ‘DHRS7C, CACNA1C, SLC8A1, RYR2, ANK2’ (GO:0010880); ‘CACNA1C, ATP2A2, RYR2, ANK2’ (GO:0098909). These genes are primarily involved in Ca2+ channels and may be the most closely associated with AF. A total of two of the most significant top 20 KEGG pathways were ‘arrhythmogenic right ventricular cardiomyopathy’ (no. ko05412) and ‘cardiac muscle contraction’ (no. ko04260), which were also associated with AF. Differential expression of circRNAs may be affected by AF and atrial remodeling. The present study identified a number of differential circRNAs in AF.

The circRNA-ceRNA interactions were constructed to examine which circRNAs serve important roles in NPAF progression. A total of nine differential circRNAs (hsa_circRNA-011785, −001321, −003878, −002085, −003884, −003876, −007410, −007411 and −004558) from calcium-associated parental genes were selected. miRNAs serve multiple roles in atrial fibrillation, including regulating electrical remodeling by targeting the genes involved in different ion channels, and regulating structural remodeling in cardiac tissues by increasing cardiac fibrosis or apoptosis. Different miRNAs have been demonstrated to be upregulated or downregulated in patients with AF (21), and may target different genes to regulate cardiac function. Different miRNAs may target single genes and serve similar roles, including repressing IK1 (potassium current) by targeting KCNJ2 via miR-1 and miR-26 (22,38). In the present study, certain circRNAs were also dysregulated in AF, which might indicate an association. The interactions between hsa_circRNA004558 and miR-208b, between hsa_circRNA002085 and hsa-miR-21, and between hsa_circRNA001321 and hsa-miR-1 may suggest a possible regulatory mechanism in AF. For instance, miR-208b was demonstrated to be upregulated in patients with AF and an ovine model. Furthermore, a high miR-208b level was demonstrated to increase MYH7 expression and alter the subcellular localization of connexin43 (39). miR-208b has been reported to reduce the expression levels of CaV1.2 and SERCA2, which further reduce L-type Ca2+ current density and sarcoplasmic reticulum Ca2+ load/release, respectively (39). These alterations are hallmarks of atrial remodeling during AF (40). miR-21 is reportedly associated with atrial fibrosis regulation in AF, which inhibits the proliferation of cardiac fibroblasts by inactivating the transforming growth factor (TGF)-β1/mothers against decapentaplegic homolog (Smad)2 signaling pathway (41).

miR-21-3p may regulate sepsis-associated cardiac dysfunction and the development of cardiac hypertrophy. When miR-21-3p is inhibited, such diseases may be treated via a protective strategy (42,43). The upregulated inward rectifier currents (IK1) associated with the electrical remodeling of AF are required to maintain AF. Additionally, miR-1 expression is downregulated in patients with AF, which may increase the levels of inwardly rectifying potassium channel (Kir)2.1 subunits and IK1 (44,45). miR-4732-3p is targeted by three circRNAs (hsa_circRNA-003876, −003878 and −003884), and represses TGF-β signaling by targeting Smad2 and Smad4, and promoting cell proliferation (46). The TGF-β and Smad signaling pathways serve essential roles in atrial fibrosis.

The results of the present study provide a potential novel insight into the molecular mechanisms and therapeutic implications of AF. The circRNA-ceRNA interactions identified may act as biosignatures for AF, and provide evidence for identifying a novel agent for the diagnosis and gene-targeted therapy of AF.

The current study has a few limitations. Firstly, though the effects of clinical patient characteristics (e.g. comorbidities, duration of AF and use of drugs) on the analysis of the RNA network were considered during patient selection, it is not possible to disregard these effects. Secondly, the circRNA data for NPAF and normal tissues were obtained from RNA sequencing, although further validation is required, including through the use of knockdown and overexpression experiments on target circRNAs and miRNAs.

Acknowledgements

Not applicable.

Funding

The present study was funded by the General Program of the National Natural Science Foundation of China (grant nos. 81500252 and 81770267, to DL), and the Outstanding Young Talent Training Program of Shanghai Municipal Commission of Health and Family Planning (grant no. 2017YQ045, to DL).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

CG and YLu conceived and designed the experiments. YZ, XK and JL performed the experiments. XM, YLi, DL and LW analyzed the data. YZ, CG and YLu wrote the paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Written informed consent from patients was obtained prior to collection of the left atrial appendages, which were abandoned due to the surgical technique. The study was approved by the ethics committees (no. 040-2017) in accordance with the relevant guidelines and regulations (clinical research registration no. ChiCTR-RRC-17014230). The patients provided written informed consent.

Patient consent for publication

The patients provided written informed consent for publication.

Competing interests

The authors declare that they have no competing interests.

Glossary

Abbreviations

Abbreviations:

circRNA

circular RNA

ceRNA

competing endogenous RNA

NPAF

nonvalvular persistent atrial fibrillation

LAA

left atrial appendages

GO

Gene Ontology

KEGG

Kyoto Encyclopedia of Genes and Genomes

AF

atrial fibrillation

FC

fold-change

RT-qPCR

reverse transcription-quantitative polymerase chain reaction

TGF-β1

transforming growth factor-β1

References

1 

Nattel S: New ideas about atrial fibrillation 50 years on. Nature. 415:219–226. 2002. View Article : Google Scholar : PubMed/NCBI

2 

Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A, Jonasdottir A, Baker A, Thorleifsson G, Kristjansson K, et al: Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 448:353–357. 2007. View Article : Google Scholar : PubMed/NCBI

3 

Du X, Dong J and Ma C: Is atrial fibrillation a preventable disease? J Am Coll Cardiol. 69:1968–1982. 2017. View Article : Google Scholar : PubMed/NCBI

4 

Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, et al: Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation. 129:837–847. 2014. View Article : Google Scholar : PubMed/NCBI

5 

Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, et al: A biomarker-based risk score to predict death in patients with atrial fibrillation: The ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 39:477–485. 2018. View Article : Google Scholar : PubMed/NCBI

6 

Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, et al: 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study. Lancet. 386:154–162. 2015. View Article : Google Scholar : PubMed/NCBI

7 

Kirchhof P: The future of atrial fibrillation management: Integrated care and stratified therapy. Lancet. 390:1873–1887. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Kotecha D, Calvert M, Deeks JJ, Griffith M, Kirchhof P, Lip GY, Mehta S, Slinn G, Stanbury M, Steeds RP and Townend JN: A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. BMJ Open. 7:e0150992017. View Article : Google Scholar : PubMed/NCBI

9 

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, et al: 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 18:1609–1678. 2016. View Article : Google Scholar : PubMed/NCBI

10 

Chiang CE, Wang KL and Lip GY: Stroke prevention in atrial fibrillation: An Asian perspective. Thromb Haemost. 111:789–797. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Fauchier L, Philippart R, Clementy N, Bourguignon T, Angoulvant D, Ivanes F, Babuty D and Bernard A: How to define valvular atrial fibrillation? Arch Cardiovasc Dis. 108:530–539. 2015. View Article : Google Scholar : PubMed/NCBI

12 

Boriani G, Cimaglia P, Fantecchi E, Mantovani V, Ziacchi M, Valzania C, Martignani C, Biffi M and Diemberger I: Non-valvular atrial fibrillation: Potential clinical implications of the heterogeneous definitions used in trials on new oral anticoagulants. J Cardiovasc Med (Hagerstown). 16:491–496. 2015. View Article : Google Scholar : PubMed/NCBI

13 

Nigro JM, Cho KR, Fearon ER, Kern SE, Ruppert JM, Oliner JD, Kinzler KW and Vogelstein B: Scrambled exons. Cell. 64:607–613. 1991. View Article : Google Scholar : PubMed/NCBI

14 

Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK and Kjems J: Natural RNA circles function as efficient microRNA sponges. Nature. 495:384–388. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, et al: Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 495:333–338. 2013. View Article : Google Scholar : PubMed/NCBI

16 

Cortés-López M and Miura P: Emerging functions of circular RNAs. Yale J Biol Med. 89:527–537. 2016.PubMed/NCBI

17 

He L, Zhang A, Xiong L, Li Y, Huang R, Liao L, Zhu Z and Wang AY: Deep circular RNA sequencing provides insights into the mechanism underlying grass carp reovirus infection. Int J Mol Sci. 18(pii): E19772017. View Article : Google Scholar : PubMed/NCBI

18 

Zhang S, Zhu DN, Li H, Li H, Feng C and Zhang W: Characterization of circRNA-associated-ceRNA networks in a senescence-accelerated mouse prone 8 brain. Mol Ther. 25:2053–2061. 2017. View Article : Google Scholar : PubMed/NCBI

19 

Nan A, Chen LJ, Zhang N, Liu Z, Yang T, Wang Z, Yang C and Jiang Y: A novel regulatory network among LncRpa, CircRar1, MiR-671 and apoptotic genes promotes lead-induced neuronal cell apoptosis. Arch Toxicol. 91:1671–1684. 2017. View Article : Google Scholar : PubMed/NCBI

20 

Audic S and Claverie JM: Self-identification of protein-coding regions in microbial genomes. Proc Natl Acad Sci USA. 95:10026–10031. 1998. View Article : Google Scholar : PubMed/NCBI

21 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

22 

Su H, Lin F, Deng X, Shen L, Fang Y, Fei Z, Zhao L, Zhang X, Pan H, Xie D, et al: Profiling and bioinformatics analyses reveal differential circular RNA expression in radioresistant esophageal cancer cells. J Transl Med. 14:2252016. View Article : Google Scholar : PubMed/NCBI

23 

Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, Sun W, Dou K and Li H: Circular RNA: A new star of noncoding RNAs. Cancer Lett. 365:141–148. 2015. View Article : Google Scholar : PubMed/NCBI

24 

Jeck WR and Sharpless NE: Detecting and characterizing circular RNAs. Nat Biotechnol. 32:453–461. 2014. View Article : Google Scholar : PubMed/NCBI

25 

Chen LL and Yang L: Regulation of circRNA biogenesis. RNA Biol. 12:381–388. 2015. View Article : Google Scholar : PubMed/NCBI

26 

Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF and Sharpless NE: Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 19:141–157. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Starke S, Jost I, Rossbach O, Schneider T, Schreiner S, Hung LH and Bindereif A: Exon circularization requires canonical splice signals. Cell Rep. 10:103–111. 2015. View Article : Google Scholar : PubMed/NCBI

28 

Guo JN, Li J, Zhu CL, Feng WT, Shao JX, Wan L, Huang MD and He JD: Comprehensive profile of differentially expressed circular RNAs reveals that hsa_circ_0000069 is upregulated and promotes cell proliferation, migration, and invasion in colorectal cancer. Onco Targets Ther. 9:7451–7458. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Galasso M, Costantino G, Pasquali L, Minotti L, Baldassari F, Corrà F, Agnoletto C and Volinia S: Profiling of the predicted circular RNAs in ductal in situ and invasive breast cancer: A pilot study. Int J Genomics. 2016:45038402016. View Article : Google Scholar : PubMed/NCBI

30 

Chen J, Li Y, Zheng Q, Bao C, He J, Chen B, Lyu D, Zheng B, Xu Y, Long Z, et al: Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett. 388:208–219. 2017. View Article : Google Scholar : PubMed/NCBI

31 

Tang CM, Zhang M, Huang L, Hu ZQ, Zhu JN, Xiao Z, Zhang Z, Lin QX, Zheng XL, Yang M, et al: CircRNA_000203 enhances the expression of fibrosis-associated genes by derepressing targets of miR-26b-5p, Col1a2 and CTGF, in cardiac fibroblasts. Sci Rep. 7:403422017. View Article : Google Scholar : PubMed/NCBI

32 

Woods CE and Olgin J: Atrial fibrillation therapy now and in the future: Drugs, biologicals, and ablation. Circ Res. 114:1532–1546. 2014. View Article : Google Scholar : PubMed/NCBI

33 

Brundel BJ, Van Gelder IC, Henning RH, Tuinenburg AE, Wietses M, Grandjean JG, Wilde AA, Van Gilst WH and Crijns HJ: Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: Differential regulation of protein and mRNA levels for K+ channels. J Am Coll Cardiol. 37:926–932. 2001. View Article : Google Scholar : PubMed/NCBI

34 

Santulli G, D'ascia SL and D'ascia C: Development of atrial fibrillation in recipients of cardiac resynchronization therapy: The role of atrial reverse remodelling. Can J Cardiol. 28:245.e17–e18. 2012. View Article : Google Scholar

35 

Xie W, Santulli G, Guo X, Gao M, Chen BX and Marks AR: Imaging atrial arrhythmic intracellular calcium in intact heart. J Mol Cell Cardiol. 64:120–123. 2013. View Article : Google Scholar : PubMed/NCBI

36 

Andrade J, Khairy P, Dobrev D and Nattel S: The clinical profile and pathophysiology of atrial fibrillation: Relationships among clinical features, epidemiology, and mechanisms. Circ Res. 114:1453–1468. 2014. View Article : Google Scholar : PubMed/NCBI

37 

Dobrev D and Nattel S: Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J Cardiovasc Pharmacol. 52:293–299. 2008. View Article : Google Scholar : PubMed/NCBI

38 

Luo X, Pan Z, Shan H, Xiao J, Sun X, Wang N, Lin H, Xiao L, Maguy A, Qi XY, et al: MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest. 123:1939–1951. 2013. View Article : Google Scholar : PubMed/NCBI

39 

Cañón S, Caballero R, Herraiz-Martinez A, Pérez-Hernández M, López B, Atienza F, Jalife J, Hove-Madsen L, Delpón E and Bernad A: miR-208b upregulation interferes with calcium handling in HL-1 atrial myocytes: Implications in human chronic atrial fibrillation. J Mol Cell Cardiol. 99:162–173. 2016. View Article : Google Scholar : PubMed/NCBI

40 

Lai LP, Su MJ, Lin JL, Lin FY, Tsai CH, Chen YS, Huang SK, Tseng YZ and Lien WP: Down-regulation of L-type calcium channel and sarcoplasmic reticular Ca(2+)-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: An insight into the mechanism of atrial electrical remodeling. J Am Coll Cardiol. 33:1231–1237. 1999. View Article : Google Scholar : PubMed/NCBI

41 

Tao H, Zhang M, Yang JJ and Shi KH: MicroRNA-21 via dysregulation of WW domain-containing protein 1 regulate atrial fibrosis in atrial fibrillation. Heart Lung Circ. 27:104–113. 2018. View Article : Google Scholar : PubMed/NCBI

42 

Wang H, Bei Y, Shen S, Huang P, Shi J, Zhang J, Sun Q, Chen Y, Yang Y, Xu T, et al: miR-21-3p controls sepsis-associated cardiac dysfunction via regulating SORBS2. J Mol Cell Cardiol. 94:43–53. 2016. View Article : Google Scholar : PubMed/NCBI

43 

Yan MW, Chen C, Gong W, Yin Z, Zhou L, Chaugai S and Wang DW: miR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8. Cardiovasc Res. 105:340–352. 2015. View Article : Google Scholar : PubMed/NCBI

44 

Girmatsion Z, Biliczki P, Bonauer A, Wimmer-Greinecker G, Scherer M, Moritz A, Bukowska A, Goette A, Nattel S, Hohnloser SH and Ehrlich JR: Changes in microRNA-1 expression and I-K1 up-regulation in human atrial fibrillation. Heart Rhythm. 6:1802–1809. 2009. View Article : Google Scholar : PubMed/NCBI

45 

Ehrlich JR: Inward rectifier potassium currents as a target for atrial fibrillation therapy. J Cardiovasc Pharmacol. 52:129–135. 2008. View Article : Google Scholar : PubMed/NCBI

46 

Doss JF, Corcoran DL, Jima DD, Telen MJ, Dave SS and Chi JT: A comprehensive joint analysis of the long and short RNA transcriptomes of human erythrocytes. BMC Genomics. 16:9522015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

January-2019
Volume 19 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang Y, Ke X, Liu J, Ma X, Liu Y, Liang D, Wang L, Guo C and Luo Y: Characterization of circRNA‑associated ceRNA networks in patients with nonvalvular persistent atrial fibrillation. Mol Med Rep 19: 638-650, 2019
APA
Zhang, Y., Ke, X., Liu, J., Ma, X., Liu, Y., Liang, D. ... Luo, Y. (2019). Characterization of circRNA‑associated ceRNA networks in patients with nonvalvular persistent atrial fibrillation. Molecular Medicine Reports, 19, 638-650. https://doi.org/10.3892/mmr.2018.9695
MLA
Zhang, Y., Ke, X., Liu, J., Ma, X., Liu, Y., Liang, D., Wang, L., Guo, C., Luo, Y."Characterization of circRNA‑associated ceRNA networks in patients with nonvalvular persistent atrial fibrillation". Molecular Medicine Reports 19.1 (2019): 638-650.
Chicago
Zhang, Y., Ke, X., Liu, J., Ma, X., Liu, Y., Liang, D., Wang, L., Guo, C., Luo, Y."Characterization of circRNA‑associated ceRNA networks in patients with nonvalvular persistent atrial fibrillation". Molecular Medicine Reports 19, no. 1 (2019): 638-650. https://doi.org/10.3892/mmr.2018.9695